Surgical strategies to synchronous colorectal liver metastases

Digestive Diseases

Volumn 30, Issue SUPPL.2, 2012, Pages 132-136

  Brouquet, Antoine ^a   Nordlinger, Bernard ^a,b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL SURGERY; CONFERENCE PAPER; CONTINUOUS INFUSION; DISEASE ASSOCIATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SYNCHRONOUS COLORECTAL LIVER METASTASIS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; PATIENT SELECTION; RECTAL NEOPLASMS; TIME FACTORS;

EID: 84870831621     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342043     Document Type: Conference Paper

References (26)

1. Nordlinger B, Guiguet M, Vaillant JC, BalladurP, Boudjema K, Bachellier P, et al: Surgicalresection of colorectal carcinoma metastasesto the liver. A prognostic scoringsystem to improve case selection, based on1,568 patients. Association Française deChirurgie. Cancer 1996; 77: 1254-1262.
2. Fong Y, Fortner J, Sun RL, Brennan MF,Blumgart LH: Clinical score for predictingrecurrence after hepatic resection for metastaticcolorectal cancer: analysis of 1,001consecutive cases. Ann Surg 1999; 230: 309-318.
3. Brouquet A, Mortenson MM, Vauthey JN,Rodriguez-Bigas MA, Overman MJ, ChangGJ, et al: Surgical strategies for synchronouscolorectal liver metastases in 156 consecutivepatients: classic, combined or reversestrategy? J Am Coll Surg 2010; 210: 934-941.
4. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL,Ribero D, Assumpcao L, et al: Simultaneousresections of colorectal cancer and synchronousliver metastases: a multi-institutionalanalysis. Ann Surg Oncol 2007; 14: 3481-3491.
5. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD: Neoadjuvantchemotherapy and resection of advancedsynchronous liver metastases before treatmentof the colorectal primary. Br J Surg2006; 93: 872-878.
6. de Gramont A, Bosset JF, Milan C, RougierP, Bouché O, Etienne PL, et al: Randomizedtrial comparing monthly low-dose leucovorinand fluorouracil bolus with bimonthlyhigh-dose leucovorin and fluorouracil bolusplus continuous infusion for advancedcolorectal cancer: a French intergroup study.J Clin Oncol 1997; 15: 808-815.
7. de Gramont A, Figer A, Seymour M, HomerinM, Hmissi A, Cassidy J, et al: Leucovorinand fluorouracil with or without oxaliplatinas first-line treatment in advancedcolorectal cancer. J Clin Oncol 2000; 18:2938-2947.
8. Douillard JY, Cunningham D, Roth AD, NavarroM, James RD, Karasek P, et al: Irinotecancombined with fluorouracil comparedwith fluorouracil alone as first-line treatmentfor metastatic colorectal cancer: a multicentrerandomised trial. Lancet 2000; 355:1041-1047.
9. Falcone A, Ricci S, Brunetti I, Pfanner E, AllegriniG, Barbara C, et al: Phase III trial ofinfusional fluorouracil, leucovorin, oxaliplatin,and irinotecan (FOLFOXIRI) comparedwith infusional fluorouracil, leucovorin,and irinotecan (FOLFIRI) as first-linetreatment for metastatic colorectal cancer:the Gruppo Oncologico Nord Ovest. J ClinOncol 2007; 25: 1670-1676.
10. Hurwitz H, Fehrenbacher L, Novotny W,Cartwright T, Hainsworth J, Heim W, et al:Bevacizumab plus irinotecan, fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004; 350: 2335-2342.
11. Van Cutsem E, Köhne CH, Hitre E, ZaluskiJ, Chang Chien CR, et al: Cetuximab andchemotherapy as initial treatment for metastaticcolorectal cancer. N Engl J Med 2009;360: 1408-1417.
12. Bokemeyer C, Bondarenko I, Makhson A,Hartmann JT, Aparicio J, de Braud F, et al:Fluorouracil, leucovorin, and oxaliplatinwith and without cetuximab in the first-linetreatment of metastatic colorectal cancer. JClin Oncol 2009; 27: 663-671.
13. Portier G, Elias D, Bouche O, Rougier P,Bosset JF, Saric J, et al: Multicenter randomizedtrial of adjuvant fluorouracil and folinicacid compared with surgery alone after resectionof colorectal liver metastases: FFCDACHBTH AURC 9002 trial. J Clin Oncol2006; 24: 4976-4982.
14. Lorenz M, Müller HH, Schramm H, GasselHJ, Rau HG, Ridwelski K, et al: Randomizedtrial of surgery versus surgery followed byadjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastasesof colorectal cancer. German Cooperativeon Liver Metastases. Ann Surg 1998; 228:756-762.
15. Kemeny N, Huang Y, Cohen AM, Shi W,Conti JA, Brennan MF, et al: Hepatic arterialinfusion of chemotherapy after resection ofhepatic metastases from colorectal cancer. NEngl J Med 1999; 341: 2039-2048.
16. Kemeny MM, Adak S, Gray B, Macdonald JS,Smith T, Lipsitz S, et al: Combined-modalitytreatment for resectable metastatic colorectalcarcinoma to the liver: surgical resectionof hepatic metastases in combination withcontinuous infusion of chemotherapy-anintergroup study. J Clin Oncol 2002; 20:1499-1505.
17. Langer B, Bleiberg H, Labianca R, ShepherdL, Nitti D, Marsoni S, et al: Fluorouracil (FU)plus leucovorin (I-LV) versus observationafter potentially curative resection of liveror lung metastases from colorectal cancer(CRC): results of the ENG (EORTC/NCICCTG/GIVIO) randomized trial (abstract592). Proc Am Soc Clin Oncol 2002; 21: 149a.
18. Mitry E, Fields A, Bleiberg H, Labianca R,Portier G, Tu D, et al: Adjuvant chemotherapyafter potentially curative resection of metastasesfrom colorectal cancer. A metaanalysisof two randomized trials. J Clin Oncol2008; 26: 4906-4911.
19. Ychou M, Hohenberger W, Thezenas S, NavarroM, Maurel J, Bokemeyer C, et al: A randomizedphase III study comparing adjuvant5-fluorouracil/folinic acid with FOLFIRI inpatients following complete resection of livermetastases from colorectal cancer. Ann Oncol2009; 20: 1964-1970.
20. Nordlinger B, Sorbye H, Glimelius B, PostonGJ, Schlag PM, Rougier P, et al: Perioperativechemotherapy with FOLFOX4 and surgeryversus surgery alone for resectable liver metastasesfrom colorectal cancer (EORTC Intergrouptrial 40983): a randomised controlledtrial. Lancet 2008; 371: 1007-1016.
21. Allen PJ, Kemeny N, Jarnagin W, DeMatteoR, Blumgart L, Fong Y, et al: Importance ofresponse to neoadjuvant chemotherapy inpatients undergoing resection of synchronouscolorectal liver metastases. J GastrointestSurg 2003; 7: 109-115.
22. Adam R, Pascal G, Castaing D, Azoulay D,Delvart V, Paule B, et al: Tumor progressionwhile on chemotherapy: a contraindicationto liver resection for multiple colorectal metastases?Ann Surg 2004; 240: 1052-1061.
23. Chun YS, Vauthey JN, Boonsirikamchai P,Maru DM, Kopetz S, Palavecino M, et al: Associationof computed tomography morphologiccriteria with pathologic response andsurvival in patients treated with bevacizumabfor colorectal liver metastases. JAMA2009; 302: 2338-2344.
24. Poultsides GA, Servais EL, Saltz LB, Patil S,Kemeny NE, Guillem JG, et al: Outcome ofprimary tumor in patients with synchronousstage IV colorectal cancer receiving combinationchemotherapy without surgery as initialtreatment. J Clin Oncol 2009; 27: 3379-3384.
25. Chua YJ, Barbachano Y, Cunningham D,Oates JR, Brown G, Wotherspoon A, et al:Neoadjuvant capecitabine and oxaliplatinbefore chemoradiotherapy and total mesorectalexcision in MRI-defined poor-riskrectal cancer: a phase 2 trial. Lancet Oncol2010; 11: 241-248.
26. Saltz LB, Clarke S, Díaz-Rubio E, ScheithauerW, Figer A, Wong R, et al: Bevacizumab incombination with oxaliplatin-based chemotherapyas first-line therapy in metastaticcolorectal cancer: a randomized phase IIIstudy. J Clin Oncol 2008;26:2013-2019.